Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 2/20 | 0.65 |
| ▸ | RXRB | P28702 | 2/20 | 0.65 |
| ▸ | RXRG | P48443 | 2/20 | 0.65 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.52 |
| ▸ | PTPN6 | P29350 | 3/20 | 0.52 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.52 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | HTR2B | P41595 | 1/20 | 0.51 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.51 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.50 |
| ▸ | SLC26A3 | P40879 | 1/20 | 0.50 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.50 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.50 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.50 |
| ▸ | PPARD | Q03181 | 1/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4723962 | 0.91 | RXRA (0.57) | RXRARXRBRXRGMRGPRX4PTPN1 | |
| SCHEMBL17141488 | 0.86 | RXRA (0.53) | RXRARXRBRXRGMRGPRX4LRRK2 | |
| SCHEMBL14098669 | 0.85 | RXRA (0.52) | RXRARXRBRXRGMRGPRX4LRRK2 | |
| SCHEMBL6211474 | 0.85 | RXRA (0.55) | RXRARXRBRXRGMRGPRX4PTPN1 | |
| SCHEMBL17141539 | 0.85 | HTR2C (0.54) | RXRARXRBRXRGMRGPRX4PTPN1 | |
| SCHEMBL4720660 | 0.84 | RXRA (0.50) | RXRARXRBRXRGMRGPRX4PTPN1 | |
| SCHEMBL7341566 | 0.83 | PTGDR2 (0.48) | RXRARXRBRXRGPTGDR2PPARD | |
| SCHEMBL17141510 | 0.82 | RXRA (0.53) | RXRARXRBRXRGMRGPRX4PTPN1 | |
| SCHEMBL6216861 | 0.82 | HTR2C (0.54) | RXRARXRBRXRGMRGPRX4PTPN1 | |
| SCHEMBL561476 | 0.82 | HTR2C (0.54) | RXRARXRBRXRGMRGPRX4PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170137415-A1 | SULFONAMIDE COMPOUNDS AS VOLTAGE GATED SODIUM CHANNEL MODULATORS | LUPIN LIMITED (IN) | 2017-05-18 | — | — | US | disclosed |
| EP-3126360-A1 | SULFONAMIDE COMPOUNDS AS VOLTAGE GATED SODIUM CHANNEL MODULATORS | Lupin Limited (IN) | 2017-02-08 | — | — | EP | disclosed |
| WO-2015151001-A1 | SULFONAMIDE COMPOUNDS AS VOLTAGE GATED SODIUM CHANNEL MODULATORS | LUPIN LIMITED (IN) | 2015-10-08 | — | — | WO | disclosed |
| US-20080207708-A1 | Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders | GLAXO GROUP LIMITED (GB) | 2008-08-28 | — | — | US | disclosed |
| US-20080207708-A1 | Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders | GLAXO GROUP LIMITED (GB) | 2008-08-28 | — | — | US | disclosed |
| US-20080207708-A1 | Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders | GLAXO GROUP LIMITED (GB) | 2008-08-28 | — | — | US | disclosed |
| EP-1874776-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PGE2 MEDIATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006114274-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PGE2 MEDIATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207708-A1 | Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders | PTGER1, PTGER2, PTGER4 | RXRA 65/4885RXRB 51/4885RXRG 131/4885 |
| US-20170137415-A1 | SULFONAMIDE COMPOUNDS AS VOLTAGE GATED SODIUM CHANNEL MODULATORS | SCN7A, SCN1A, SCN5A | RXRA 3944/4885RXRB 4067/4885RXRG 3924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.